[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2003240495A1 - Diagnostics markers for lung cancer - Google Patents

Diagnostics markers for lung cancer

Info

Publication number
AU2003240495A1
AU2003240495A1 AU2003240495A AU2003240495A AU2003240495A1 AU 2003240495 A1 AU2003240495 A1 AU 2003240495A1 AU 2003240495 A AU2003240495 A AU 2003240495A AU 2003240495 A AU2003240495 A AU 2003240495A AU 2003240495 A1 AU2003240495 A1 AU 2003240495A1
Authority
AU
Australia
Prior art keywords
lung cancer
diagnostics
markers
diagnostics markers
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003240495A
Other versions
AU2003240495A8 (en
Inventor
Randi Krasnow
Paula K. Rickert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2003240495A8 publication Critical patent/AU2003240495A8/en
Publication of AU2003240495A1 publication Critical patent/AU2003240495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AU2003240495A 2002-06-04 2003-06-02 Diagnostics markers for lung cancer Abandoned AU2003240495A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38600502P 2002-06-04 2002-06-04
US60/386,005 2002-06-04
PCT/US2003/017409 WO2003101283A2 (en) 2002-06-04 2003-06-02 Diagnostics markers for lung cancer

Publications (2)

Publication Number Publication Date
AU2003240495A8 AU2003240495A8 (en) 2003-12-19
AU2003240495A1 true AU2003240495A1 (en) 2003-12-19

Family

ID=29712224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003240495A Abandoned AU2003240495A1 (en) 2002-06-04 2003-06-02 Diagnostics markers for lung cancer

Country Status (2)

Country Link
AU (1) AU2003240495A1 (en)
WO (1) WO2003101283A2 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
EP3120861B1 (en) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
US20060078558A1 (en) * 2003-11-12 2006-04-13 Whitsett Jeffrey A Diagnosis, prognosis and treatment of pulmonary diseases
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
KR20120064120A (en) 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
EA012799B1 (en) 2004-08-16 2009-12-30 Кварк Фармасьютикалс, Инк. Therapeutic uses of inhibitors of rtp801
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1802749B1 (en) 2004-10-21 2012-08-22 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders
US8227194B2 (en) * 2005-04-08 2012-07-24 University Of Maryland, Baltimore Monoclonal antibodies with binding specificity for response gene to complement 32 (RGC-32)
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
DOP2007000015A (en) 2006-01-20 2007-08-31 Quark Biotech Inc THERAPEUTIC USES OF RTP801 INHIBITORS
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801l
JP2010518880A (en) 2007-02-26 2010-06-03 クアーク・ファーマスーティカルス、インコーポレイテッド Inhibitors of RTP801 and their use in the treatment of diseases
LT2769729T (en) 2007-09-04 2019-05-10 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
PL2781913T3 (en) * 2007-09-11 2018-08-31 Cancer Prevention And Cure, Ltd. Method for aiding in the diagnosis and therapy of asthma and lung cancer
CA2702590A1 (en) * 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
CN113189342A (en) 2009-03-12 2021-07-30 癌症预防和治疗有限公司 Methods and kits for identifying, assessing, preventing and treating lung diseases
SG176947A1 (en) 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
ES2567030T3 (en) * 2009-09-03 2016-04-19 Cancer Research Technology Limited CLEC14A inhibitors
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
SG181814A1 (en) 2009-12-23 2012-07-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
RS52983B (en) 2010-04-15 2014-02-28 Spirogen Sárl Pyrrolobenzodiazepines and conjugates thereof
MX336540B (en) 2010-06-08 2016-01-22 Genentech Inc Cysteine engineered antibodies and conjugates.
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
PE20141114A1 (en) 2010-12-20 2014-09-15 Genentech Inc ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES
DK2665746T3 (en) 2011-01-17 2021-02-01 Lykera Biomed S A Antibodies against the s100p protein for the treatment and diagnosis of cancer
WO2012123295A1 (en) * 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Fen1 as marker for chronic obstructive pulmonary disease (copd)
CA2833404A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
KR101992502B1 (en) 2011-05-12 2019-06-24 제넨테크, 인크. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
CA2836855C (en) 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2750713B1 (en) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EP2756093A4 (en) 2012-02-01 2015-07-01 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
HUE041274T2 (en) 2012-10-12 2019-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
ES2649990T3 (en) 2012-10-12 2018-01-16 Medimmune Limited Anti-CD22-pyrrolobenzodiazepine antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057117A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
SI2766048T1 (en) 2012-10-12 2015-03-31 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CN110452242A (en) 2012-12-21 2019-11-15 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN105307685B (en) 2013-03-13 2019-03-08 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
CN105142674B (en) 2013-03-13 2018-11-13 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
ES2687439T3 (en) 2013-03-13 2018-10-25 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20160042080A (en) 2013-08-12 2016-04-18 제넨테크, 인크. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SG11201604905WA (en) 2013-12-16 2016-07-28 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
BR112016012410A2 (en) 2013-12-16 2017-09-26 Genentech Inc drug-antibody conjugate, drug-antibody conjugate, non-peptide compound, method of treating human disease and pharmaceutical composition
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
MX2017003523A (en) 2014-09-17 2017-11-08 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof.
KR20170101895A (en) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugates
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (en) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Protac antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN109689111B (en) 2016-08-11 2024-04-05 基因泰克公司 Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
PT3544636T (en) 2017-02-08 2021-05-04 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018187496A2 (en) 2017-04-04 2018-10-11 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
ES2926144T3 (en) 2017-04-18 2022-10-24 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2019012464A (en) 2017-04-20 2019-12-11 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate.
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
RS62928B1 (en) 2017-08-18 2022-03-31 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RU2020113749A (en) 2017-09-20 2021-10-20 пиЭйч ФАРМА Ко., ЛТД. ANALOGUES OF THAILANSTATIN
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (en) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
JP2022513198A (en) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Also Published As

Publication number Publication date
WO2003101283A2 (en) 2003-12-11
WO2003101283A3 (en) 2004-12-09
AU2003240495A8 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
AU2003240495A1 (en) Diagnostics markers for lung cancer
AU2003294828A1 (en) Specific markers for pancreatic cancer
AU2002360766A1 (en) Methods for cancer imaging
AU2003241839A1 (en) Air-conditioning apparatus
AU2003266949A1 (en) Compounds
AU2003221098A1 (en) Oligofluorenylene compounds
AU2003258649A1 (en) High-density nrom-finfet
AU2003276447A1 (en) Inhalers
AU2003302877A1 (en) X-ray system
AU2003263611A1 (en) Method for diagnosing prostate cancer
AU2001270082A1 (en) Gene markers for lung cancer
AU2003215376A1 (en) Methods for diagnosing akathisia
AU2003256995A1 (en) Method for identifying cancer risk
AU2003264488A1 (en) Immunotherapeutic for cancer
AU2003216859A1 (en) Amidoacetonitrile compounds
AU2003202205A1 (en) Methods for identifying cancer risk
AU2003221050A1 (en) Remedy for hypermyotonia
AU2003236161A1 (en) Stapler
AU2003272964A1 (en) Remedy for hormone-dependent cancer
AU2003235325A1 (en) Stapler
AU2003261720A1 (en) Stapler
AU2003903349A0 (en) Template system
AU2003276671A1 (en) Intra-airway ventilation apparatus
AU2003227645A1 (en) Method for characterizing primary tumors
AU2003292667A1 (en) Benzocycloheptapyridine compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase